CompletedPhase 1

Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane

United States25 participantsStarted 2021-09-14

Plain-language summary

The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.

Who can participate

Age range18 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women, * Age 18-65, * Not pregnant, Not currently breast feeding * No current illness, Exclusion Criteria: * Pregnancy, currently breast feeding * Current illness, * History of cardiac, or renal disease

What they're measuring

Participants With 95% Reduction in Topoisomerase 2 b From Baseline

Timeframe: 8 hours after dexrazoxane administration

Trial details

NCT IDNCT03930680

SponsorUniversity of Arkansas

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-11

Results submitted2025-04-21

View on ClinicalTrials.gov More Degradation of Top2b and Top2a in Human by Dexrazoxane trials